Next Level Private LLC Buys 13,543 Shares of Pfizer Inc. (NYSE:PFE)

Next Level Private LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 31.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 56,877 shares of the biopharmaceutical company's stock after acquiring an additional 13,543 shares during the quarter. Next Level Private LLC's holdings in Pfizer were worth $1,441,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of PFE. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter worth about $26,000. Clarity Asset Management Inc. bought a new stake in Pfizer in the 4th quarter worth about $27,000. Gould Capital LLC increased its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the 4th quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer in the 4th quarter worth about $30,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Stock Down 1.2%

NYSE PFE opened at $23.11 on Friday. The stock has a market cap of $131.36 billion, a PE ratio of 16.39, a P/E/G ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock's 50 day moving average is $22.97 and its 200 day moving average is $25.01. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.82 EPS. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.44%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.